Cover Image
Market Research Report

Biosimilars Market: By Product (Recombinant Glycosated Proteins and Others) Technology (mAbs, Chromatography, Mass Spectroscopy and Others); By Application (Blood & Oncology Diseases, Chronic Diseases and Others); By Geography-Forecast 2019 - 2024

Published by IndustryARC Product code 409046
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Biosimilars Market: By Product (Recombinant Glycosated Proteins and Others) Technology (mAbs, Chromatography, Mass Spectroscopy and Others); By Application (Blood & Oncology Diseases, Chronic Diseases and Others); By Geography-Forecast 2019 - 2024
Published: December 11, 2018 Content info:
Description

"Biosimilars are subsequent entry biologics (SEB) which are introduced into the market as the original biologic approaches patent expiry. Unlike the biologics, biosimilars are expressed in living cells which brings variability in the properties of the biosimilars. Hence, they possess properties similar to the biologic instead of being an exact copy of the original drug.

Biosimilars are emerging as one of the most important sector in the healthcare industry. With increasing healthcare costs, biosimilars are looked upon as an affordable treatment option. The report explains that global biosimilars market is segmented on the basis of product types, technology, application and geography.

Based on the technologies commercially available as biosimilars, the market is segmented as:

Monoclonal Antibodies Technology

Recombinant DNA Technology

Chromatography

Nuclear Magnetic Resonance Technology

Electrophoresis

Mass Spectrometry

Western Blotting

Bioassay

Based on product types, biosimilars are classified into Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides while their applications include Blood Disorders, Oncology Disease, Chronic and Autoimmune Diseases along with Growth Hormone Deficiency under Others category. Each of these segments is further broken down to give an in-depth analysis of the market across various applications and covers the market demand with respect to regions.

The Biosimilars market is driven by increased demand from the application sector such as blood disorders, oncology diseases, chronic diseases and many others. Economic turmoil in Europe is yet another factor which adds to the demand for biosimilars market. Reverse Innovation will drive down the overall development costs and hence, the high discounting on biosimilars will motivate the patient to opt for it in the long run.

The developed markets such as the U.S. and Europe have been the forefront runner. Majority of drugs are currently being developed in these regions. In today's emerging markets, biosimilars are still nascent, with little to no presence. The growing investor confidence, pressure to reduce costs and discounting is driving the market. On the contrary, lack of awareness and physician scepticism is acting as restraints. With respect to regulatory pathways, the system is in place for developed countries. Problem lies with countries such as China, India and Russia that are still trying to device the pathway.

Sample Companies Profiled in this Report are:

Novartis International AG

Hospira Inc.

Celltrion Pharma Inc.

Biocon Limited,

Teva Pharmaceutical Industries Ltd,

10+.

Competitive analysis for biosimilars market is highlighted and market players are outlined and are examined on disparate aspects like company overview coupled with financial overview, product portfolio and recent developments."

Table of Contents

1. Global Biosimilars Market - Device Overview

2. Executive Summary

3. Global Biosimilars - Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End user profiling
    • 3.2.3. Patent Analysis
    • 3.2.4. Top 5 Financials Analysis

4. Global Biosimilars - Market Forces

  • 4.1. Market Drivers
  • 4.2. Market Constraints
  • 4.3. Market Challenges
  • 4.4. Attractiveness of the Biosimilars Industry

5. Global Biosimilars - Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Biosimilars Market, By Technology

  • 6.1. Monoclonal Antibodies Technology
  • 6.2. Nuclear Magnetic Resonance Technology
  • 6.3. Recombinant DNA Technology
  • 6.4. Chromatography
  • 6.5. Mass Spectroscopy
  • 6.6. Electrophoresis
  • 6.7. Western Blotting
  • 6.8. Bioassay

7. Biosimilars Market, By Product Type

  • 7.1. Recombinant Non-Glycosylated Protein
    • 7.1.1. Human Growth Harmone
    • 7.1.2. Insulin
    • 7.1.3. Interferon
    • 7.1.4. Granulocyte colony stimulating factor (G-CSF)
    • 7.1.5 Others
  • 7.2. Recombinant Glycosated Proteins
    • 7.2.1. Erythropoietin
    • 7.2.2. Monoclonal antibodies
    • 7.2.3. Others
  • 7.3. Peptides

8. Biosimilars Market, By Application

  • 8.1. Blood disorders
  • 8.2. Oncology Diseases
  • 8.3. Chronic and autoimmune diseases
  • 8.4. Growth hormone deficiency
  • 8.5. Multimodal Nonlinear Optical (NLO) Imaging

9. Global Biosimilars-Regulatory Landscape Analysis

  • 9.1. Regulations in United States
  • 9.2. Regulations in Europe
  • 9.3. Regulation in Asia
  • 9.4. Comparison of Biosimilar medicine guidelines

10. Geographical Landscape - Biosimilars, By Region

  • 10.1. Americas
  • 10.2. Europe
  • 10.3. Asia-Pacific
  • 10.4. Rest of The World

11. Global Biosimilars- Market Entropy

  • 11.1. New Product Launches
  • 11.2. M&As, Collaborations, JVs and Partnerships

12. Company Profiles

  • 12.1. Novaritis(Sandoz)
  • 12.2. Teva
  • 12.3. Hospira
  • 12.4. Biocon
  • 12.5. Mylan
  • 12.6. Ranbaxy
  • 12.7. Watson
  • 12.8. Actavis
  • 12.9. Apotex
  • 12.10. Stada
  • 12.11. Other generics manufacturers
  • 12.12. Pfizer
  • 12.13. GlaxoSmithKline
  • 12.14. Eli Lilly
  • 12.15. Dr Reddy's
  • 12.16. Wockhardt
  • 12.17. Cipla

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

13. Appendix

  • 13.1. Abbreviations
  • 13.2. Sources
  • 13.3. Research Methodology
  • 13.4. Expert Insights
  • 13.5. The ARC Advantage
Back to Top